Statistical Considerations for Clinical Trials During COVID-19: Impacts on Minimization Randomization and Mitigations

Qing Liu; Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Impacts on Minimization Randomization and Mitigations

Biostatistics, Epidemiology & Environmental Health Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Randomization is an essential feature of the clinical trial design (Armitage, 1982). Randomization mitigates potential for experimental bias, promotes comparability of treatment groups, and validates the use of statistical methods for inferential analysis of trial results.

Original language	American English
Journal	LinkedIn
State	Published - May 8 2020

Disciplines

Biostatistics
Environmental Public Health
Epidemiology
Public Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://www.linkedin.com/pulse/statistical-considerations-clinical-trials-during-asa-fellow-4e/?trackingId=e%2BDl4Ty0R5qlqAdTQLi3Xw%3D%3D

Cite this

@article{2ddc6a9b654649c983593e6ecb1c3cd6,

title = "Statistical Considerations for Clinical Trials During COVID-19: Impacts on Minimization Randomization and Mitigations",

abstract = " Randomization is an essential feature of the clinical trial design (Armitage, 1982). Randomization mitigates potential for experimental bias, promotes comparability of treatment groups, and validates the use of statistical methods for inferential analysis of trial results.",

author = "Qing Liu and Peace, {Karl E.}",

year = "2020",

month = may,

day = "8",

language = "American English",

journal = "LinkedIn",

}

TY - JOUR

T1 - Statistical Considerations for Clinical Trials During COVID-19: Impacts on Minimization Randomization and Mitigations

AU - Liu, Qing

AU - Peace, Karl E.

PY - 2020/5/8

Y1 - 2020/5/8

N2 - Randomization is an essential feature of the clinical trial design (Armitage, 1982). Randomization mitigates potential for experimental bias, promotes comparability of treatment groups, and validates the use of statistical methods for inferential analysis of trial results.

AB - Randomization is an essential feature of the clinical trial design (Armitage, 1982). Randomization mitigates potential for experimental bias, promotes comparability of treatment groups, and validates the use of statistical methods for inferential analysis of trial results.

UR - https://digitalcommons.georgiasouthern.edu/bee-facpubs/150

UR - https://www.linkedin.com/pulse/statistical-considerations-clinical-trials-during-asa-fellow-4e/?trackingId=e%2BDl4Ty0R5qlqAdTQLi3Xw%3D%3D

M3 - Article

JO - LinkedIn

JF - LinkedIn

ER -

Statistical Considerations for Clinical Trials During COVID-19: Impacts on Minimization Randomization and Mitigations

Abstract

Disciplines

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this